Research progress in the third-generation genomic editing technology - CRISPR/Cas9.
10.3760/cma.j.issn.1003-9406.2016.05.030
- Author:
Yalan ZHOU
1
;
Yanan ZONG
;
Xiangdong KONG
Author Information
1. Center of Prenatal Diagnosis, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China. Email: kongxd@263.net.
- Publication Type:Journal Article
- MeSH:
Biomedical Research;
methods;
trends;
CRISPR-Cas Systems;
genetics;
Gene Editing;
methods;
Genome, Human;
genetics;
Humans;
Models, Genetic;
Reproducibility of Results
- From:
Chinese Journal of Medical Genetics
2016;33(5):713-716
- CountryChina
- Language:Chinese
-
Abstract:
CRISPR/Cas9 technology originated from type II CRISPR/Cas system, which is widely found in bacteria and equips them with acquired immunity against viruses and plasmids. CRISPR-associated protein Cas9 is a RNA-guided endonuclease, which can efficiently introduce double-strand breaks at specific sites and activate homologous recombination and/or non-homologous end joining mechanism for the repair of impaired DNA. Features such as easy-to-use, cost-effectiveness, multiple targeting ability have made it the third-generation genomic engineering tool following ZFNs and TALENs. Here the history of discovery and molecular mechanism of the CRISPR/Cas9 technology are reviewed. The rapid advance in its various applications, especially for the treatment of human genetic disorders, as well as some concomitant problems are discussed.
